ICAD INVESTOR RELATIONS UPDATE

Conant, MD, is a professor of Radiology, Division of Breast Imaging and the Vice Chair of Faculty Development in the Department of Radiology at the University of Pennsylvania, Perelman School of Medicine. Nepute affiliates with many hospitals, including Indiana University Health-Arnett.Д®mily F. Having more than 12 years of diverse experiences in diagnostic radiology, Dr.

He graduated with honors from Vanderbilt University School of Medicine in 2008. Joshua Nepute, MD, is a Diagnostic Radiology Specialist in West Lafayette, Indiana. GrГ¤wingholt is currently co-chair of the ECIBC's (European Commission Initiative on Breast Cancer) Guidelines Development Group. He has 28 years of experience in breast imaging, reading 10,000 to 15,000 mammograms per year, and 10 years of tomosynthesis experience in diagnostic mammography. Hall has established the Karma Cohort, a prospective screening cohort of approximately 70,000 women.ДЄxel GrГ¤wingholt, MD, is head of the department of mammography screening in the 'Radiologie am Theater' practice in Paderborn, Germany. His research interest is focused on breast cancer screening and prevention. Hall is also an honorary consultant physician at the Department of Oncology, SГ¶dersjukhuset, Stockholm, Sweden. He works at the Department of Medical Epidemiology and Biostatistics at the Karolinska Institute in Stockholm, Sweden. Per Hall, MD, PhD, is a medical oncologist by training. To register for the webinar, please click here. Trained with one of the largest available 3D image datasets, ProFound AI provides radiologists with crucial information, such as lesion Certainty of Finding and Case Scores, which assist in clinical decision-making and prioritizing caseloads. Intended to be used by radiologists reviewing DBT images, ProFound AI rapidly and accurately analyzes each individual image or slice and identifies potentially malignant lesions. ProFound AI for DBT, or 3D mammography, is a high-performing workflow solution featuring the latest in deep-learning artificial intelligence capabilities.

ICAD INVESTOR RELATIONS UPDATE

ICAD's management team will also provide an update on the comprehensive ProFound AI technology platform. GrГ¤wingholt, Hall, Nepute, and Conant will be available to answer questions following the formal presentations. In September 2020, compelling research published in Radiology concluded that the ProFound AI Risk model is effective at identifying women at high likelihood of being diagnosed with breast cancer within two years of a negative screening mammogram and in possible need of supplemental screening.Дrs.

Conant, MD (University of Pennsylvania Perelman School of Medicine), who will discuss the current landscape for digital breast tomosynthesis (DBT) and the potential for iCAD's recently introduced ProFound AI Risk, the first and only commercially available clinical decision support tool that provides an accurate two-year breast cancer risk estimation based solely on a screening mammogram. Nepute, MD (Indiana University Health-Arnett), and Emily F. The call will feature presentations by KOLs, Per Hall, MD, PhD (Karolinska Institutet), Axel GrГ¤wingholt, MD (Radiologie am Theater), Joshua A. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it will host a key opinion leader (KOL) webinar for investors on its expanded ProFound AIВ® portfolio, including its recently introduced breast cancer risk-assessment solution that is helping transform breast cancer screening from age-based screening to risk-adaptive precision screening, on Monday, December 7, 2020, from 11:00 AM вЂ“ 1:00 PM Eastern Time.

Icad investor relations